Author
 |
TAI, ES - NAT UNIV OF SINGAPORE |
|
Ordovas, Jose |
|
Submitted to: Current Opinion in Lipidology
Publication Type: Review Article Publication Acceptance Date: 4/14/2008 Publication Date: 8/1/2008 Citation: Tai, E., Ordovas, J.M. 2008. Clinical significance of apolipoprotein A5. Current Opinion in Lipidology. 19(4):349-354. Interpretive Summary: Technical Abstract: We have investigated the evidence from recent human studies examining the role of apolipoprotein A-V (APOA-V) in triglyceride-rich lipoprotein metabolism and cardiovascular disease (CVD) risk. Special emphasis was placed on the evidence emerging from the association between genetic variability at the apolipoprotein A5(APOA5) locus, lipid phenotypes, and disease outcomes. Moreover, we address recent reports evaluating APOA5 gene–environment interactions in relation to cardiovascular disease and its common risk factors. Several genetic association studies have continued to strengthen the position of APOA5 as a major gene that is involved in triglyceride (TG) metabolism and modulated by dietary factors and pharmacological therapies. Genetic variants at this locus have been significantly associated with both coronary disease and stroke risks. APO-V has an important role in lipid metabolism, specifically for triglyceride rich lipoproteins. However, its mechanism of action is still poorly understood. Clinical significance at this time comes largely from studies showing consistent association of APOA5 gene variants with plasma triglyceride concentrations. Moreover, the effects of common genetic variants on TG concentrations and disease risk are further modulated by other factors such as diet, pharmacological interventions, and body mass index. Therefore, these genetic variants could be potentially used to predict cardiovascular disease risk and to individualize therapeutic options to decrease CVD. |
